Ga direct naar de inhoud

Ga direct naar de navigatie

Uitgave van

Archief voor de categorie ‘Farma ondernemingen’

FDA expands Janssen’s Stelara to cover adolescent psoriasis patients

Janssen has announced that the FDA has approved an expanded indication for its psoriasis therapy Stelara (ustekinumab) for the treatment of moderate to severe plaque forms of the disease in adolescent patients aged 12 or over who are candidates for phototherapy or systemic therapy.

Bron: Pharmafile Meer lezen »

BMS agrees deal on Opdivo availability through Cancer Drugs Fund for head and neck cancer

Thanks to successful negotiation of a managed access agreement, NICE has announced its recommendation of Bristol-Myers Squibb’s Opdivo (nivolumab) for inclusion in the Cancer Drugs Fund (CDF) for the treatment of squamous cell carcinoma of the head and neck which has metastasized in patients who have not responded to chemotherapy within six months.

Bron: Pharmafile Meer lezen »

Lilly’s phase 3 miss dents Verzenio prospects in hot lung cancer field

Eli Lilly’s Verzenio needs to stand out in a new class of cancer meds, and the company was hoping success in lung cancer patients with a particular mutation could be just the ticket. But its ambitions in that department have now taken a hit.

Bron: FiercePharma Meer lezen »

Roche’s 99% accurate Zika test receives FDA approval

Roche has revealed that the FDA has given approval to its cobas Zika test to determine whether a blood sample is infected with the virus. The test is to be used to screen blood donations to ensure that the virus is not transmitted through the blood supply network.  

Bron: Pharmafile Meer lezen »

AstraZeneca Chairman wants three-year Brexit transition period

The Chairman of AstraZeneca, Leif Johansson, revealed in no uncertain terms that his company would like there to be a three-year Brexit transition period.  

Bron: Pharmafile Meer lezen »

CureTech reclaims rare disease drug from Pfizer for $20 million

CureTech, a biotech firm owned by Clal Biotechnology Industries, is set to reclaim a drug it sold more than two years ago, paying $20 million to Pfizer for pidilizumab, a treatment for diffuse intrinsic pontine glioma (DIPG).  

Bron: Pharmafile Meer lezen »

FDA awards Roche priority review in HER2-positive breast cancer

Roche has revealed that its monoclonal antibody Perjeta (pertuzumab) has been awarded priority review by the FDA as an adjuvant treatment for HER2-positive early breast cancer in combination with Herceptin (trastuzumab) and chemotherapy.  

Bron: Pharmafile Meer lezen »

MSD pulls out of hep C space to Gilead’s relief

MSD, known as Merck in North America, has announced that it will curtail its attempts to make an impact in the hepatitis C space, citing a crowded marketplace as its reason. The reality is that Gilead has been able to build such a strong lead in the space, and with AbbVie making progress with Mavyret, there […]

Bron: Pharmafile Meer lezen »

‘Oplossing dure medicijnen zit in ander betaalmodel’

Farmaceuten vertellen dat ze minder hoge winsten moeten nastreven heeft geen zin. Wel kun je als samenleving andere voorwaarden stellen aan wat er tegenover die winsten komt te staan. Dat betoogt gezondheidseconoom Xander Koolman.

Bron: Skipr Meer lezen »

BMS’ Opdivo to finally be made available to lung cancer patients in the UK

It is two and a half years since patients with lung cancer in the US were able to receive Bristol-Myers Squibb’s Opdivo for treatment, the UK has finally caught up after NICE’s approval of the drug.  

Bron: Pharmafile Meer lezen »

« Oudere artikelen |